Jul. 24 at 9:41 AM
$PFE Pfizer sees a large addressable market here, given Padcev's strong phase 3 clinical trial results: It reduced the risk of death or recurrence by 50% compared to the current standard of care in cisplatin-eligible patients with bladder cancer, when combined with Keytruda. This indication could add hundreds of millions of dollars -- perhaps over
$1 billion -- to Padcev's peak sales. That may not seem like a lot for a company that generated over
$60 billion in revenue last year, but it could land several such regulatory wins, which will add label expansions across its drug portfolio and eventually improve sales growth.
